Related Experiment Video
Updated: Apr 29, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.1K
Chemotherapy-induced neuropathy: A comprehensive survey
1Department of Neuro-oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.
Cancer Treatment Reviews
|May 17, 2014
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, often disabling side effect of cancer drugs. Current treatments lack significant efficacy, necessitating research into neuroprotective strategies and personalized risk assessment.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of various anti-cancer drugs.
- Pathophysiology involves axonopathy and neuronopathy, but mechanisms vary by drug class.
- CIPN presents with sensory, motor, and autonomic symptoms, impacting quality of life and treatment outcomes.
Purpose of the Study:
- To provide an update on chemotherapy-induced peripheral neuropathy (CIPN).
- To review drug-related characteristics, pharmacogenomics, neurophysiology, treatment, and outcomes.
- To discuss neuroprotective strategies for CIPN.
Main Methods:
- Literature review of CIPN.
- Analysis of drug-specific characteristics and associated pathophysiology.
- Examination of pharmacogenomic data and neurophysiological findings.
- Evaluation of current and potential treatment strategies.
Main Results:
- CIPN is a complex condition with varied mechanisms and symptoms.
- Risk factors include drug dosage, schedule, comorbidities, and genetic polymorphisms.
- Existing preventive and treatment strategies show limited efficacy.
Conclusions:
- Understanding CIPN pathophysiology and risk factors is crucial for management.
- Pharmacogenomics may identify high-risk individuals.
- Further research into effective neuroprotective and treatment strategies is essential.
